Close

Audentes Therapeutics IPO Info

Company Name: Audentes Therapeutics
Stock Symbol: BOLD
Exchange: NASDAQ
Status: Priced
IPO Date: 7/20/2016
IPO Price: 15.00 (21.80%)
Underwriters
BofA Merrill Lynch, Cowen and Company and Piper Jaffray

Amount of Offering: N/A
Number of Shares Offered: 5 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Audentes is a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. They believe that gene therapy has powerful potential to treat these diseases through delivery of a functional copy of the affected gene to cells, resulting in production of the normal protein. The company has built a compelling portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy, or XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome, or Crigler-Najjar, AT982 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia, or CASQ2-CPVT. Audentes plans to submit Investigational New Drug applications, or INDs, or Clinical Trial Authorisations, or CTAs, for AT982 in the third quarter of 2016, for AT342 in the fourth quarter of 2016 and for AT132 in the first quarter of 2017, and expect to have preliminary data from all three programs in the second half of 2017. Audentes maintains full global rights to all of their product candidate

News Headlines